Andon Health's low P/S ratio is due to poor revenue performance and negative growth forecast. Without top-line growth improvement, the P/S ratio could fall further. The market doesn't anticipate revenue improvement justifying a higher P/S ratio.
The trends in Andon Health's ROCE seem promising as it progresses from losses to profit, indicating good internal reinvestment. The 645% total return over the past five years points to high future performance expectations.
九安医疗股票讨论区
很会赚钱的公司,为啥股票价格不给力呢?
暂无评论